Author

Meijie Chen

University of Science and Technology of ChinaORCID 0000-0001-5742-4160Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

Meiming SuiD· 2 shared Stefan OffermannsiD· 2 shared Suowen XuiD· 2 shared Yanjun YiniD· 2 shared Zhihua WangiD· 2 shared Bradford C. BerkiD· 1 shared D. Danielle KamatoiD· 1 shared Dongdong WangiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPhysiology

Meiming SuORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

PhysiologybioRxivPreprintJun 29, 2026

Tirzepatide attenuates atherosclerosis through weight loss-independent anti-inflammatory mechanisms

Shuo Chen, Shulin Wei, Tian Tian…·Suowen Xu

This paper shows tirzepatide reduces atherosclerosis independently of weight loss by directly targeting vascular inflammation through the cAMP/PKA/eNOS pathway.

DOI 10.64898/2026.06.22.733886

mousestatistical model

𝕏 PostBluesky

Pharmacology & ToxicologyScience AdvancesPeer-reviewedMar 26, 2025

The clinical antiprotozoal drug halofuginone promotes weight loss by elevating GDF15 and FGF21

Suowen Xu, Zhenghong Liu, Tian Tian…·Jianping Weng

This study shows halofuginone, an FDA-approved drug, reduces obesity in mice by increasing FGF21 and GDF15 levels, improving metabolic health.

13 citations

mousebulk RNA-seq

𝕏 PostBluesky